Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House Bill Would Eliminate COVID-19 Drug, Vaccine Cost-Sharing For Most Americans

Executive Summary

After failing to get many co-pay waivers in earlier coronavirus relief legislation, the House tries again – with an even bolder ask covering more Americans. The bill would also speed up CDC’s guidance on vaccines and ensure Medicare Part D plans cover all coronavirus treatments. But its not clear whether the Senate will get on board.

You may also be interested in...



Antibiotics Could See New Boosts From Medicare Rule, House Bill

US House looks to give BARDA more money for antibiotic development in next coronavirus relief bill, while Medicare broadens the types of antibiotics eligible for additional payments to include drugs approved under FDA's limited population antibiotic development pathway. But it's unclear whether the House funding can make it through the Senate and how meaningful the Medicare provision will be given few LPAD approvals.

Federal Official Would Monitor 'Price Gouging’ Under Latest US House Pandemic Relief Bill

Legislation also provides the US Biomedical Advanced Research and Development Authority with $3.5bn to advance research and development, manufacturing, production and the purchase of vaccines and therapeutics.

'Price Gouging’ Would Be Monitored By COVID-19 Medical Supplies Coordinator Under US House Bill

Legislation also provides the US Biomedical Advanced Research and Development Authority with $3.5bn to advance research and development, manufacturing, production and the purchase of vaccines and therapeutics.

Related Content

Topics

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel